ABT 378 AND RITONAVIR IN PROTEASE INHIBITOR EXPERIENCED HIV INFECTED PATIENTS

ABT 378 和利托那韦用于蛋白酶抑制剂治疗 HIV 感染患者

• 批准号: 6304159
• 负责人: Robert F Murphy
• 金额: $ 2.05万
• 依托单位: NORTHWESTERN UNIVERSITY AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6304159
• 关键词: AIDS therapy; HIV infections; antiAIDS agent; clinical research; clinical trial phase I; combination chemotherapy; drug screening /evaluation; human subject; human therapy evaluation; nevirapine; protease inhibitor; reverse transcriptase inhibitors; ritonavir

This study's primary objective is to assess the safety, tolerability, and antiviral activity of ABT-378/ritonavir in combination with two nucleoside reverse transcriptase inhibitors (at least one of which the patient has not received before) and nevirapine in protease inhibitor experienced HIV-infected patients. The secondary objective is to determine the steady-state pharmacokinetic profile of ABT-378/ritonavir and nevirapine in protease inhibitor experienced HIV-infected patients.

本研究的主要目的是评估ABT-378/利托那韦联合两种核苷类逆转录酶抑制剂（至少一种患者之前未接受过）和奈韦拉平治疗蛋白酶抑制剂治疗的HIV感染患者的安全性、耐受性和抗病毒活性。 次要目的是确定ABT-378/利托那韦和奈韦拉平在经历过蛋白酶抑制剂的HIV感染患者中的稳态药代动力学特征。